Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.

Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, McDonald EJ, Killick S, Hellström-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J.

J Clin Oncol. 2013 Oct 1;31(28):3557-64. doi: 10.1200/JCO.2012.45.5626. Epub 2013 Sep 3.

PMID:
24002510
2.

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Germing U, Agirre X, Prosper F, Aul C, Killick S, Wainscoat JS, Schuh A, Boultwood J.

Haematologica. 2013 Dec;98(12):1856-64. doi: 10.3324/haematol.2013.086686. Epub 2013 Jul 5.

3.

Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

Yip BH, Vuppusetty C, Attwood M, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, Maciejewski JP, Vandenberghe P, Mecucci C, Wainscoat JS, Pellagatti A, Boultwood J.

Leukemia. 2013 Aug;27(8):1760-3. doi: 10.1038/leu.2013.20. Epub 2013 Jan 22. No abstract available.

PMID:
23337929
4.

Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34⁺ progenitor cells.

Davies C, Yip BH, Fernandez-Mercado M, Woll PS, Agirre X, Prosper F, Jacobsen SE, Wainscoat JS, Pellagatti A, Boultwood J.

Br J Haematol. 2013 Mar;160(6):842-50. doi: 10.1111/bjh.12217. Epub 2013 Jan 8.

PMID:
23294243
5.

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts.

Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-Blanco T, Giai V, Fernandez-Mercado M, Papaemmanuil E, Högstrand K, Jansson M, Vedin I, Wainscoat JS, Campbell P, Cazzola M, Boultwood J, Grandien A, Hellström-Lindberg E.

Leukemia. 2013 Apr;27(4):889-896. doi: 10.1038/leu.2012.298. Epub 2012 Oct 16.

6.

Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.

Boultwood J, Yip BH, Vuppusetty C, Pellagatti A, Wainscoat JS.

Adv Biol Regul. 2013 Jan;53(1):8-17. doi: 10.1016/j.jbior.2012.09.002. Epub 2012 Sep 13. Review.

PMID:
23031788
7.

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T, Pérez C, Killick S, McDonald EJ, Odero MD, Agirre X, Prósper F, Calasanz MJ, Wainscoat JS, Boultwood J.

PLoS One. 2012;7(8):e42334. doi: 10.1371/journal.pone.0042334. Epub 2012 Aug 9.

8.

5q- syndrome.

Boultwood J, Pellagatti A, Wainscoat JS.

Curr Pharm Des. 2012;18(22):3180-3. Review.

PMID:
22571696
9.

Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

Yip BH, Pellagatti A, Vuppusetty C, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, Fernandez-Mercado M, McDonald EJ, Killick S, Wainscoat JS, Boultwood J.

Leukemia. 2012 Sep;26(9):2154-8. doi: 10.1038/leu.2012.82. Epub 2012 Mar 20. No abstract available.

PMID:
22430631
10.

TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.

Pérez C, Martínez-Calle N, Martín-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, Garate L, Alvarez S, Rifon J, Varea S, Boultwood J, Wainscoat JS, Cruz Cigudosa J, Calasanz MJ, Cross NC, Prósper F, Agirre X.

PLoS One. 2012;7(2):e31605. doi: 10.1371/journal.pone.0031605. Epub 2012 Feb 6.

11.

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E, Groves MJ, Godfrey AL, Ambaglio I, Gallì A, Da Vià MC, Conte S, Tauro S, Keenan N, Hyslop A, Hinton J, Mudie LJ, Wainscoat JS, Futreal PA, Stratton MR, Campbell PJ, Hellström-Lindberg E, Cazzola M; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative.

Blood. 2011 Dec 8;118(24):6239-46. doi: 10.1182/blood-2011-09-377275. Epub 2011 Oct 12.

12.

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.

N Engl J Med. 2011 Oct 13;365(15):1384-95. doi: 10.1056/NEJMoa1103283. Epub 2011 Sep 26.

13.

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.

Boultwood J, Pellagatti A, Wainscoat JS.

Adv Biol Regul. 2012 Jan;52(1):196-203. Review. No abstract available.

PMID:
21930148
14.

Genomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal or incomplete karyotype.

Ballabio E, Regan R, Garimberti E, Harbott J, Bradtke J, Teigler-Schlegel A, Biondi A, Cazzaniga G, Giudici G, Wainscoat JS, Boultwood J, Bridger JM, Knight SJ, Tosi S.

PLoS One. 2011;6(6):e20607. doi: 10.1371/journal.pone.0020607. Epub 2011 Jun 9.

15.

Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes.

Roy NB, Myerson S, Schuh AH, Bignell P, Patel R, Wainscoat JS, McGowan S, Marchi E, Atoyebi W, Littlewood T, Chacko J, Vyas P, Killick SB.

Br J Haematol. 2011 Aug;154(4):521-4. doi: 10.1111/j.1365-2141.2011.08749.x. Epub 2011 Jun 21.

PMID:
21689086
16.

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.

Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Lawrie CH.

Biol Direct. 2011 May 18;6:23. doi: 10.1186/1745-6150-6-23.

17.

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.

Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Vyas P, Hellström-Lindberg E, Wainscoat JS, Boultwood J.

Br J Haematol. 2011 Oct;155(2):272-4. doi: 10.1111/j.1365-2141.2011.08672.x. Epub 2011 Apr 15. No abstract available.

PMID:
21492127
18.

Advances in the 5q- syndrome.

Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS.

Blood. 2010 Dec 23;116(26):5803-11. doi: 10.1182/blood-2010-04-273771. Epub 2010 Aug 23. Review.

PMID:
20733155
19.

MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential.

Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, Tosi I, Vermeer MH, Tramonti D, Saunders NJ, Boultwood J, Wainscoat JS, Pezzella F, Whittaker SJ, Tensen CP, Hatton CS, Lawrie CH.

Blood. 2010 Aug 19;116(7):1105-13. doi: 10.1182/blood-2009-12-256719. Epub 2010 May 6.

20.

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.

Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, Pellagatti A, Wang L, Clark RE, Wainscoat JS.

Leukemia. 2010 Jun;24(6):1139-45. doi: 10.1038/leu.2010.65. Epub 2010 Apr 22.

PMID:
20410925
21.

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.

Nikpour M, Pellagatti A, Liu A, Karimi M, Malcovati L, Gogvadze V, Forsblom AM, Wainscoat JS, Cazzola M, Zhivotovsky B, Grandien A, Boultwood J, Hellström-Lindberg E.

Br J Haematol. 2010 Jun;149(6):844-54. doi: 10.1111/j.1365-2141.2010.08174.x. Epub 2010 Apr 12.

PMID:
20408843
22.

Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome.

Pellagatti A, Marafioti T, Paterson JC, Barlow JL, Drynan LF, Giagounidis A, Pileri SA, Cazzola M, McKenzie AN, Wainscoat JS, Boultwood J.

Blood. 2010 Apr 1;115(13):2721-3. doi: 10.1182/blood-2009-12-259705. No abstract available.

PMID:
20360478
23.

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.

Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Verma A, Norbury CJ, Hellström-Lindberg E, Wainscoat JS, Boultwood J.

Leukemia. 2010 Apr;24(4):756-64. doi: 10.1038/leu.2010.31. Epub 2010 Mar 11.

PMID:
20220779
24.

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.

Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, Larrayoz MJ, Garcia-Delgado M, Giagounidis A, Malcovati L, Della Porta MG, Jädersten M, Killick S, Hellström-Lindberg E, Cazzola M, Wainscoat JS.

Leukemia. 2010 May;24(5):1062-5. doi: 10.1038/leu.2010.20. Epub 2010 Feb 25. No abstract available.

PMID:
20182461
25.

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, Jolin HE, Pannell R, Middleton AJ, Wong SH, Warren AJ, Wainscoat JS, Boultwood J, McKenzie AN.

Nat Med. 2010 Jan;16(1):59-66. doi: 10.1038/nm.2063. Epub 2009 Nov 22.

26.

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Jädersten M, Saft L, Pellagatti A, Göhring G, Wainscoat JS, Boultwood J, Porwit A, Schlegelberger B, Hellström-Lindberg E.

Haematologica. 2009 Dec;94(12):1762-6. doi: 10.3324/haematol.2009.011528. Epub 2009 Oct 1.

27.

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Gallì A, Travaglino E, Brisci A, Rumi E, Passamonti F, Invernizzi R, Cremonesi L, Boultwood J, Wainscoat JS, Hellström-Lindberg E, Cazzola M.

Blood. 2009 Oct 22;114(17):3538-45. doi: 10.1182/blood-2009-05-222331. Epub 2009 Aug 19.

PMID:
19692701
28.

MicroRNA expression in chronic lymphocytic leukaemia.

Lawrie CH, Ballabio E, Dyar OJ, Jones M, Ventura R, Chi J, Tramonti D, Gooding S, Boultwood J, Wainscoat JS, Hatton CS, Schuh A.

Br J Haematol. 2009 Nov;147(3):398-402. doi: 10.1111/j.1365-2141.2009.07857.x. Epub 2009 Aug 13. No abstract available.

PMID:
19681887
29.

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.

Pellagatti A, Marafioti T, Paterson JC, Malcovati L, Della Porta MG, Jädersten M, Pushkaran B, George TI, Arber DA, Killick S, Giagounidis A, Hellström-Lindberg E, Cazzola M, Wainscoat JS, Boultwood J.

Br J Haematol. 2009 Jun;146(1):86-90. doi: 10.1111/j.1365-2141.2009.07720.x. Epub 2009 May 5.

PMID:
19438482
30.

Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma.

Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS.

J Cell Mol Med. 2009 Jul;13(7):1248-60. doi: 10.1111/j.1582-4934.2008.00628.x. Epub 2008 Dec 24.

31.

Expression profiling of persistent polyclonal B-cell lymphocytosis suggests constitutive expression of the AP-1 transcription complex and downregulation of Fas-apoptotic and TGFbeta signalling pathways.

Lawrie CH, Shilling R, Troussard X, Cattan H, Mossafa H, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS.

Leukemia. 2009 Mar;23(3):581-3. doi: 10.1038/leu.2008.223. Epub 2008 Aug 28. No abstract available.

PMID:
18754033
32.

Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.

Wang L, Fidler C, Nadig N, Giagounidis A, Della Porta MG, Malcovati L, Killick S, Gattermann N, Aul C, Boultwood J, Wainscoat JS.

Haematologica. 2008 Jul;93(7):994-1000. doi: 10.3324/haematol.12603. Epub 2008 May 27.

33.

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.

Pellagatti A, Hellström-Lindberg E, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Fidler C, Cazzola M, Wainscoat JS, Boultwood J.

Br J Haematol. 2008 Jul;142(1):57-64. doi: 10.1111/j.1365-2141.2008.07178.x. Epub 2008 May 8. Erratum in: Br J Haematol. 2009 Feb;144(3):455.

34.

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.

Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H, Littlewood TJ, Malcovati L, Della Porta MG, Jädersten M, Killick S, Giagounidis A, Bowen D, Hellström-Lindberg E, Cazzola M, Wainscoat JS.

PLoS One. 2008 Apr 9;3(4):e1970. doi: 10.1371/journal.pone.0001970.

35.

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.

Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL.

Br J Haematol. 2008 May;141(5):672-5. doi: 10.1111/j.1365-2141.2008.07077.x. Epub 2008 Mar 3.

PMID:
18318758
36.

MicroRNA expression in lymphocyte development and malignancy.

Lawrie CH, Saunders NJ, Soneji S, Palazzo S, Dunlop HM, Cooper CD, Brown PJ, Troussard X, Mossafa H, Enver T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS.

Leukemia. 2008 Jul;22(7):1440-6. doi: 10.1038/sj.leu.2405083. Epub 2008 Jan 10. No abstract available.

PMID:
18185523
37.

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.

Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L, Della Porta MG, Jädersten M, Killick S, Fidler C, Cazzola M, Hellström-Lindberg E, Wainscoat JS.

Br J Haematol. 2007 Nov;139(4):578-89. Epub 2007 Oct 3.

PMID:
17916100
38.

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, Wainscoat JS, Boultwood J, Hellström-Lindberg E.

Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11. Epub 2007 Jun 18.

39.

Gene silencing by DNA methylation in haematological malignancies.

Boultwood J, Wainscoat JS.

Br J Haematol. 2007 Jul;138(1):3-11. Epub 2007 May 9. Review.

PMID:
17489980
40.

MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.

Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, Wainscoat JS, Hatton CS.

Int J Cancer. 2007 Sep 1;121(5):1156-61.

41.
42.

The role of cell-free DNA size distribution in the management of prostate cancer.

Boddy JL, Gal S, Malone PR, Shaida N, Wainscoat JS, Harris AL.

Oncol Res. 2006;16(1):35-41.

PMID:
16783966
43.

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, Campbell LJ, Wang L, Langford CF, Fidler C, Oscier D, Aul C, Wainscoat JS, Boultwood J.

Blood. 2006 Jul 1;108(1):337-45. Epub 2006 Mar 9. Erratum in: Blood. 2006 Aug 15;108(4):1128.

PMID:
16527891
44.

hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.

Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J.

Leukemia. 2006 Apr;20(4):671-9.

PMID:
16498395
45.

Gene expression profiling in the myelodysplastic syndromes.

Pellagatti A, Fidler C, Wainscoat JS, Boultwood J.

Hematology. 2005 Aug;10(4):281-7. Review.

PMID:
16085540
46.

Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.

Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB.

Genes Chromosomes Cancer. 2005 Nov;44(3):279-91.

PMID:
16015647
47.

Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease.

Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS.

Clin Cancer Res. 2005 Feb 15;11(4):1394-9.

48.

The 5q- syndrome.

Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C.

Hematology. 2004 Aug;9(4):271-7.

PMID:
15621734
49.

High-mobility group A (HMGA) genes: from solid to liquid tumours?

Boultwood J, Wainscoat JS.

Leukemia. 2005 Feb;19(2):195-6. No abstract available.

PMID:
15618962
50.

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.

Boultwood J, Pellagatti A, Watkins F, Campbell LJ, Esoof N, Cross NC, Eagleton H, Littlewood TJ, Fidler C, Wainscoat JS.

Br J Haematol. 2004 Aug;126(4):508-11.

PMID:
15287943

Supplemental Content

Loading ...
Support Center